Standard engineering technology Limited has announced a plant visit for analysts and investors scheduled for March 23, 2026, in Hyderabad. The company informed both BSE Limited and National Stock Exchange of India Limited about this event through a regulatory filing dated March 16, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Event Details

The plant visit is organized as a full-day in-person meeting by the company's management. The event details are structured as follows:

Regulatory Compliance and Disclosure

The company has emphasized its commitment to regulatory compliance by clearly stating that the event is conducted under Part A of Schedule III of the SEBI regulations. Standard Engineering Technology Limited has provided specific assurances regarding the nature of discussions during the visit.

The management has clarified that all discussions with analysts and institutional investors will be based exclusively on industry and company-specific developments that are already in the public domain. The company has explicitly stated that no unpublished price-sensitive information pertaining to the company will be shared or discussed during the interactions.

Important Considerations

The company has noted that the schedule is subject to changes due to potential exigencies on the part of analysts, investors, or the company itself. This flexibility clause ensures that the event can be adjusted if necessary circumstances arise.

The announcement was signed by Kallam Hima Priya, Company Secretary and Compliance Officer, who digitally signed the document on March 16, 2026. Standard Engineering Technology Limited, formerly known as Standard Glass Lining Technology Limited, operates with its registered office in Hyderabad and maintains multiple certifications including ISO 9001, ISO 14001, ISO 27001, and ISO 45001.

Standard Engineering Technology Limited has announced the execution of a target-based conditional distribution agreement with API Pharma Pharmaceutical Trading L.L.C for the Middle East region. The agreement, disclosed under Regulation 30 of SEBI regulations on March 05, 2026, forms part of the company's strategic export expansion initiative.

Agreement Structure and Timeline

The distribution agreement establishes a performance-linked framework with specific commercial milestones. Key terms of the arrangement include:

The agreement's continuation beyond the initial three-year period depends on achieving predetermined business targets, creating a risk-calibrated model for market expansion.

Target Markets and Industries

The partnership will focus on strengthening Standard Engineering Technology Limited's presence across multiple sectors in the Middle East region:

• Pharmaceutical manufacturing facilities
• Biopharmaceutical and life sciences
• Food & beverages
• Other process industries

The company noted that the Middle East region continues to witness sustained investments in pharmaceutical self-sufficiency, biopharma capacity creation, food security programs, and diversified industrial infrastructure under long-term economic transformation initiatives.

Partner Details and Commercial Structure

The agreement does not involve any shareholding arrangements, and API Pharma Pharmaceutical Trading L.L.C is not related to the promoter, promoter group, or group companies. The transaction does not fall within related party transactions.

Risk Management and Commercial Protections

Recognizing evolving geopolitical developments in certain parts of the Middle East region, Standard Engineering Technology Limited has structured the agreement with commercial protections and periodic review mechanisms. This approach allows the company to participate in export-driven growth opportunities while maintaining prudent risk management.

Strategic Significance

The distribution agreement enables Standard Engineering Technology Limited to access Middle East markets through a performance-linked model, potentially contributing to foreign revenue growth. Under the arrangement, the company will export its manufactured products and services to customers of API Pharma Pharmaceutical Trading L.L.C in the Middle East region, expanding its regional customer network and enhancing export volumes.